Jean‐François Laprise

1.5k total citations
33 papers, 1.0k citations indexed

About

Jean‐François Laprise is a scholar working on Epidemiology, Surgery and Health. According to data from OpenAlex, Jean‐François Laprise has authored 33 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Epidemiology, 9 papers in Surgery and 6 papers in Health. Recurrent topics in Jean‐François Laprise's work include Cervical Cancer and HPV Research (27 papers), Hepatitis B Virus Studies (18 papers) and Genital Health and Disease (8 papers). Jean‐François Laprise is often cited by papers focused on Cervical Cancer and HPV Research (27 papers), Hepatitis B Virus Studies (18 papers) and Genital Health and Disease (8 papers). Jean‐François Laprise collaborates with scholars based in Canada, United Kingdom and United States. Jean‐François Laprise's co-authors include Marc Brisson, Mélanie Drolet, Marie‐Claude Boily, Harrell W. Chesson, Lauri E. Markowitz, Mark Jit, Eduardo L. Franco, Talía Malagón, Élodie Bénard and Dave Martin and has published in prestigious journals such as Annals of Internal Medicine, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Jean‐François Laprise

30 papers receiving 997 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jean‐François Laprise Canada	19	824	275	216	148	116	33	1.0k
Rayleen M. Lewis United States	12	649 0.8×	274 1.0×	144 0.7×	96 0.6×	165 1.4×	19	888
Nathalie Largeron France	20	809 1.0×	255 0.9×	293 1.4×	154 1.0×	54 0.5×	64	1.1k
Lea E. Widdice United States	13	555 0.7×	260 0.9×	114 0.5×	63 0.4×	112 1.0×	43	674
Géraldine Dominiak-Felden France	9	690 0.8×	359 1.3×	114 0.5×	113 0.8×	77 0.7×	9	838
Vanessa Rémy France	15	435 0.5×	151 0.5×	288 1.3×	75 0.5×	89 0.8×	20	739
Michele Kohli United States	13	714 0.9×	319 1.2×	184 0.9×	145 1.0×	66 0.6×	31	1.2k
Tanja Y. Walker United States	14	1.1k 1.4×	226 0.8×	570 2.6×	166 1.1×	98 0.8×	18	1.3k
Talía Malagón Canada	14	735 0.9×	308 1.1×	81 0.4×	195 1.3×	93 0.8×	34	916
Cecily Banura Uganda	17	528 0.6×	211 0.8×	137 0.6×	129 0.9×	58 0.5×	30	855
Sarah Reagan-Steiner United States	11	1.0k 1.2×	283 1.0×	514 2.4×	181 1.2×	91 0.8×	23	1.6k

Countries citing papers authored by Jean‐François Laprise

Since Specialization

Citations

This map shows the geographic impact of Jean‐François Laprise's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐François Laprise with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐François Laprise more than expected).

Fields of papers citing papers by Jean‐François Laprise

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐François Laprise. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐François Laprise. The network helps show where Jean‐François Laprise may publish in the future.

Co-authorship network of co-authors of Jean‐François Laprise

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐François Laprise. A scholar is included among the top collaborators of Jean‐François Laprise based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐François Laprise. Jean‐François Laprise is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brisson, Marc, Jean‐François Laprise, Mélanie Drolet, et al.. (2024). Population-level impact of switching to 1-dose human papillomavirus vaccination in high-income countries: examining uncertainties using mathematical modeling. JNCI Monographs. 2024(67). 387–399.

Drolet, Mélanie, Jean‐François Laprise, Chantal Sauvageau, et al.. (2024). Switching from a 2-dose to a 1-dose program of gender-neutral routine vaccination against human papillomavirus in Canada: a mathematical modelling analysis. Canadian Medical Association Journal. 196(33). E1136–E1143.

Laprise, Jean‐François, Harrell W. Chesson, Lauri E. Markowitz, Mélanie Drolet, & Marc Brisson. (2024). Cost-Effectiveness of Extending Human Papillomavirus Vaccination to Population Subgroups Older Than 26 Years Who Are at Higher Risk for Human Papillomavirus Infection in the United States. Annals of Internal Medicine. 178(1). 50–58. 4 indexed citations

Bénard, Élodie, Mélanie Drolet, Jean‐François Laprise, et al.. (2023). Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis. The Lancet Public Health. 8(10). e788–e799. 23 indexed citations

Prem, Kiesha, Yoon Hong Choi, Élodie Bénard, et al.. (2023). Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis. BMC Medicine. 21(1). 313–313. 30 indexed citations

Burger, Emily A., Jean‐François Laprise, Stephen Sy, et al.. (2022). Now or later: Health impacts of delaying single‐dose HPV vaccine implementation in a high‐burden setting. International Journal of Cancer. 151(10). 1804–1809. 9 indexed citations

Bénard, Élodie, Mélanie Drolet, Jean‐François Laprise, et al.. (2022). Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis. The Lancet Global Health. 11(1). e48–e58. 8 indexed citations

Drolet, Mélanie, Jean‐François Laprise, Dave Martin, et al.. (2021). Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis. The Lancet Infectious Diseases. 21(11). 1598–1610. 56 indexed citations

Chesson, Harrell W., Jean‐François Laprise, Marc Brisson, & Lauri E. Markowitz. (2016). Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine. The Journal of Infectious Diseases. 213(11). 1694–1700. 29 indexed citations

10.

Simms, Kate T., Jean‐François Laprise, Megan A. Smith, et al.. (2016). Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis. The Lancet Public Health. 1(2). e66–e75. 29 indexed citations

11.

Laprise, Jean‐François, Lauri E. Markowitz, Harrell W. Chesson, Mélanie Drolet, & Marc Brisson. (2016). Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. The Journal of Infectious Diseases. 214(5). 685–688. 29 indexed citations

12.

Brisson, Marc, Jean‐François Laprise, Harrell W. Chesson, et al.. (2015). Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States. JNCI Journal of the National Cancer Institute. 108(1). djv282–djv282. 80 indexed citations

13.

Jit, Mark, Marc Brisson, Jean‐François Laprise, & Yeon Hee Choi. (2015). Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ. 350(jan06 14). g7584–g7584. 54 indexed citations

14.

Malagón, Talía, Mélanie Drolet, Marie‐Claude Boily, Jean‐François Laprise, & Marc Brisson. (2014). Changing Inequalities in Cervical Cancer: Modeling the Impact of Vaccine Uptake, Vaccine Herd Effects, and Cervical Cancer Screening in the Post-Vaccination Era. Cancer Epidemiology Biomarkers & Prevention. 24(1). 276–285. 10 indexed citations

15.

Jit, Mark, Yoon Hong Choi, Jean‐François Laprise, et al.. (2014). Two-dose strategies for human papillomavirus vaccination: How well do they need to protect?. Vaccine. 32(26). 3237–3242. 22 indexed citations

16.

Laprise, Jean‐François, Mélanie Drolet, Marie‐Claude Boily, et al.. (2014). Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study. Vaccine. 32(44). 5845–5853. 50 indexed citations

17.

Drolet, Mélanie, Marie‐Claude Boily, Christina Greenaway, et al.. (2013). Sociodemographic Inequalities in Sexual Activity and Cervical Cancer Screening: Implications for the Success of Human Papillomavirus Vaccination. Cancer Epidemiology Biomarkers & Prevention. 22(4). 641–652. 38 indexed citations

18.

Brisson, Marc, Jean‐François Laprise, Mélanie Drolet, et al.. (2013). Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study. Vaccine. 31(37). 3863–3871. 43 indexed citations

19.

Drolet, Mélanie, Jean‐François Laprise, Marie‐Claude Boily, Eduardo L. Franco, & Marc Brisson. (2013). Potential cost‐effectiveness of the nonavalent human papillomavirus (HPV) vaccine. International Journal of Cancer. 134(9). 2264–2268. 65 indexed citations

20.

Velde, Nicolas Van de, Marie‐Claude Boily, Mélanie Drolet, et al.. (2012). Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis. JNCI Journal of the National Cancer Institute. 104(22). 1712–1723. 110 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact